開催まで1週間!! オンコロジーコンサルタントが注目する 米国臨床腫瘍学会 (ASCO) 2019 のトピックをご紹介

今年の米国臨床腫瘍学会（American Society of Clinical Oncology: ASCO）のテーマは「Caring for Every Patient, Learning from Every Patient」。先日Abstractも発表され、5,000以上の研究が発表される見込みです。サイニクスからも数名が渡米し、Cerner Enviza℠ のコンサルタントとともに情報収集のため広い学会会場を奔走します。弊社社員を見かけられました際には、ぜひお気軽にお声をかけていただけますと幸いです。

ASCO 2019の注目トピック

膀胱がん

・EV-201: Results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and immune checkpoint inhibitors
AORAL ABSTRACT SESSION / Genitourinary (Nonprostate) Cancer
日時　2019年6月3日（月） 8:00 AM – 11:00 AM
会場　Arie Crown Theater

乳がん

・SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). (Abstract 1000 )
ORAL ABSTRACT SESSION / Genitourinary (Nonprostate) Cancer  
日時　2019年6月3日（月） 8:00 AM – 11:00 AM
会場　Arie Crown Theater

・Capivasertib (AZD5363) plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER-positive breast cancer (FAKTION): A randomized, double-blind, placebo-controlled, phase II trial. (Abstract 1005)
ORAL ABSTRACT SESSION / Breast Cancer—Metastatic
日時　2019年6月4日（火） 9:45 AM- 12:45 PM
会場　Hall D1

胃がん

・Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
ORAL ABSTRACT SESSION / Gastrointestinal (Noncolorectal) Cancer
日時　2019年6月2日（日） 9:45 AM – 12:45 PM
会場　Arie Crown Theater

肝細胞がん

・A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).
ORAL ABSTRACT SESSION / Developmental Immunotherapy and Tumor Immunobiology
日時　2019年6月2日（日） 8:00 AM – 11:00 AM
会場　Hall D2

多発性骨髄腫

・Phase 3 randomized study of daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) vs VTd in transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 1 results.

・Efficacy and safety of the randomized, open-label, non-inferiority, phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA.

・A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM).

ORAL ABSTRACT SESSION / Hematologic Malignancies—Plasma Cell Dyscrasia
日時　2019年6月2日（日）9:45 AM – 12:45 PM
会場　E451

膵臓がん

・Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.
PLENARY SESSION / Plenary Session Including the Distinguished Achievement Award and Science of Oncology Award Lecture
日時　2019年6月2日（日） 1:00 PM – 4:00 PM
会場　Hall B1

前立腺がん

・TOPARP-B: A phase II randomized trial of the poly(ADP)-ribose polymerase (PARP) inhibitor olaparib for metastatic castration resistant prostate cancers (mCRPC) with DNA damage repair (DDR) alterations.
ORAL ABSTRACT SESSION / Genitourinary (Prostate) Cancer
日時　2019年5月31日（金） 2:45 PM – 5:45 PM
会場　Arie Crown Theater

・Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC).
ORAL ABSTRACT SESSION / Genitourinary (Prostate) Cancer
日時　2019年5月31日（金） 2:45 PM – 5:45 PM
会場　Arie Crown Theater

非ホジキンリンパ腫

・Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open label, registration directed phase II study.

ORAL ABSTRACT SESSION / Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
日時　2019年6月4日（火） 9:45 AM – 12:45 PM
会場　E451

非小細胞肺がん

・RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated patients with epidermal growth factor receptor mutation-positive (EGFRm) metastatic non-small cell lung cancer (NSCLC)

ORAL ABSTRACT SESSION / Lung Cancer—Non-Small Cell Metastatic
日時　2019年6月3日（月） 8:00 AM – 11:00 AM
会場　Hall B1

腎細胞がん

・Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).
ORAL ABSTRACT SESSION / Genitourinary (Nonprostate) Cancer
日時　2019年6月3日（月）  8:00 AM – 11:00 AM
会場　Arie Crown Theater